SLN SLN
Company Profile ↓Company Overview
SLN (SLN) is a publicly traded company listed on with a market capitalization of $1.59B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Dec 2025 Revenue of $559.00K (-98.7% YoY); net profit $-88.61M.
- Trailing 12 Months Year-on-year growth — revenue -98.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -70.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -70.45% |
| 1 Year: | -98.71% |
Stock Price Performance
| 1 Year: | +82.17% |
| 6 Months: | +132.23% |
| 3 Months: | +57.42% |
| 1 Month: | +10.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -70.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.70M | 756.00K | 1.50M | - | 142.00K | 224.00K | 159.00K | 34.00K | 422.00K |
| Cost of Revenue | - | - | - | - | 54.00K | 85.00K | 64.00K | 12.00K | 11.00K |
| Gross Profit | 12.90M | -2.58M | -2.14M | - | 88.00K | 139.00K | 95.00K | 22.00K | 411.00K |
| Operating Expenses | - | - | - | - | 28.50M | 22.78M | 26.34M | 12.48M | 16.15M |
| Operating Income | -5.58M | -23.39M | -30.00M | - | -28.41M | -22.64M | -26.24M | -12.46M | -15.74M |
| EBITDA | - | - | - | - | -28.27M | -22.49M | -26.09M | -12.35M | -15.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -28.53M | -27.34M | -20.96M | -11.77M | -14.96M |
| Tax Provision | - | - | - | - | 0 | 10.00K | 1.00K | 0 | 0 |
| Net Income | -2.31M | -19.75M | -35.54M | - | -28.53M | -27.35M | -20.96M | -11.77M | -14.96M |
| Diluted EPS | -0.02 | -0.14 | -0.25 | - | -0.60 | -0.57 | -0.45 | - | -0.33 |
| R&D Expense | 11.85M | 13.80M | 20.16M | - | 20.81M | 17.65M | 20.54M | - | 9.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 21.66M | 31.64M | 43.26M | 559.00K |
| Cost of Revenue | - | 13.46M | 12.87M | 11.81M | 215.00K |
| Gross Profit | - | 8.19M | 18.78M | 31.45M | 344.00K |
| Operating Expenses | - | 69.23M | 83.16M | 94.77M | 90.10M |
| Operating Income | - | -61.04M | -64.38M | -63.32M | -89.75M |
| EBITDA | - | -60.44M | -63.76M | -62.73M | -89.20M |
| Interest Expense | 10.80K | 56.88K | 43.31K | - | - |
| Pretax Income | - | -49.65M | -53.27M | -44.46M | -88.60M |
| Tax Provision | - | 688.00K | 956.00K | 845.00K | 11.00K |
| Net Income | - | -50.33M | -54.23M | -45.31M | -88.61M |
| Diluted EPS | - | -1.56 | -1.47 | -0.99 | -1.89 |
| R&D Expense | - | 43.55M | 56.94M | 67.88M | 67.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 130.10M | 119.45M | 202.63M | 131.44M |
| Current Assets | - | 117.01M | 103.15M | 187.37M | 118.66M |
| Cash & Equivalents | - | 66.34M | 68.79M | 121.33M | 11.28M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.11M | 290.00K | 972.00K | 0 |
| Total Liabilities | - | 103.38M | 97.45M | 68.61M | 69.14M |
| Current Liabilities | - | 26.56M | 22.34M | 16.82M | 13.61M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 539.75K | 346.00K | 117.00K | 160.00K |
| Total Equity | - | 26.71M | 21.99M | 134.02M | 62.30M |
| Shares Outstanding | - | 107.81M | 118.85M | 141.67M | 141.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -57.04M | -49.46M | -67.64M | -62.27M |
| Investing Cash Flow | - | -20.50M | 19.29M | -21.97M | -47.99M |
| Financing Cash Flow | - | 52.58M | 31.94M | 142.09M | 15.00K |
| Capital Expenditure | - | -545.00K | -56.00K | -211.00K | -55.00K |
| Free Cash Flow | - | -57.59M | -49.52M | -67.85M | -62.33M |
| Net Change in Cash | - | -24.96M | 1.77M | 52.48M | -110.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 37.8% | 59.3% | 72.7% | 61.5% |
| Operating Margin % | - | -281.9% | -203.5% | -146.4% | -16,056.0% |
| Net Margin % | - | -232.4% | -171.4% | -104.7% | -15,851.9% |
| ROE % | - | -188.4% | -246.6% | -33.8% | -142.2% |
| ROCE % | - | -59.0% | -66.3% | -34.1% | -76.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLN
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbGhjM0ExZlFBV082OE1tVkphUC1wU05PeTFjX0ZQc1RMbnFpNjBKaERGaFpQd05kOXhldmR0aUtydDV2RHZvdkdBOFlEXzBHcGdIc1MzOUNFeG1CTG1DUTNBaDdYY0pJSVBrUWliRTRjMDFTQUQ5SllvRnMxaGlDdXMxdGdNSlVQQktGUk…
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY2F0LWpSWXFCaHc3UjBWc2owTUFDOF9Demh2MjhqVURBNVZxbGQtcl9BLXpoZmQwS2JqRXVBOWd4eEF3UUpXVXI4MVh2UDhid1ZJc19GX05PZkZiZ1I1RXIzYlNTc2U0MWtRd09KVVVPYzc1dEFTZnNoLU5fam1PWVZiWU9wVkVvaG5ZTH…
Why Is Silence Therapeutics Stock Soaring Wednesday? - Silence Therapeutics (NASDAQ:SLN) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRWNkZGd3RHNlQjBZUnZwR3A3ajNHZmNjT3RXRlZpcWZCU3NYZGpNUkpnZVFfVmdzV0Z3c2drVDlyUVdZZFVheElVdVdzWnBYMU90anh2VnVidHk4T1N5QWVSaWhJU21iNE1xSzc3WTh2UU1kdFV4c0lmZXdNYlhkbjNkUmg3aXNxcTM1c2…
Silence Therapeutics Plc - American Depository Share Revenue Breakdown – NASDAQ:SLN - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1KZThmeVZNRUZJcW9HLUdKUmZSU2VnOUc5T2hodkZURi1INkxLLXZsQ0h6TFk2cVhOUFFhVklPYlA5X0JOSUo1V2JubnF0QWNRYk5uRWxXbUtNUVJFYUZBOGQ0UzlNN2VqcXRuUEF6UWQ0RTZXS0E?oc=5" target="_blank">Silence …
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNeDVMd2Z6c09rSHN4TE1lWGYxZi1TdmNObUNJNHdKX1lWTW9nN1FCU1QySmNYb1R6dUplcm82cm14WEVjaDlSQXFwVTYxZkQxZEpUOENRVl9jenRfRmU4LURSVFdudUJpY0pjd3BaMjlUMkRZWVR1MkxrZjVqYUZmUDd6REcyZU85YlhobH…
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPTVA1UlhhbEU1VTFrWDdHaE51RmNWRFJGY1VDZnpTSXppWElLYjFPVDF4VlZZOXV3SUR4ZEd5YmFmZFlNMWFQVTl2d003NjQyVkppS1RlM0xYaXJUWHdBMzlCeER3Ynl0ZkZ5MzlPNkFqa0VzU21BR1NQQk9FNmMwNG5OLUhsUmNmVlpab2…
SLN — Frequently Asked Questions
What is the current share price of SLN?
As of 2026-08-05 17:25 PDT, SLN trades at $11.24 on NASDAQ/NYSE. Its 52-week range is $4.30 to $12.07.
What is the market capitalisation of SLN?
SLN has a market capitalisation of $1.59B on NASDAQ/NYSE.
What is the P/E ratio of SLN?
SLN trades at a trailing price-to-earnings (P/E) ratio of -5.95. Its price-to-book (P/B) ratio is 25.56.
What is the return on equity (ROE) of SLN?
SLN has a return on equity (ROE) of -142.23%. Its return on capital employed (ROCE) is -76.17%.
Is SLN a good stock to buy?
This page provides a data-driven analysis of SLN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.